REGENXBIO's Duchenne Gene Therapy Shows Functional, Cardiac Benefits in Phase I/II Trial
Event summary
- RGX-202 demonstrated positive interim data from Phase I/II AFFINITY DUCHENNE trial, showing functional improvements and cardiac stability in Duchenne patients.
- Pivotal dose participants exceeded external controls across functional measures at one year, including those aged 8+.
- No serious adverse events or adverse events of special interest observed, with favorable safety profile continued.
- Topline pivotal data expected in Q2 2026, with pre-BLA meeting with FDA planned for mid-2026.
The big picture
REGENXBIO's positive interim data for RGX-202 underscores the potential of gene therapy in treating Duchenne muscular dystrophy, a debilitating and progressive disease. The favorable safety profile and functional improvements observed in the Phase I/II trial highlight the strategic importance of RGX-202 in REGENXBIO's pipeline, particularly as the company prepares for pivotal data readouts and regulatory discussions. The success of RGX-202 could significantly impact the gene therapy landscape for rare diseases, positioning REGENXBIO as a key player in this evolving market.
What we're watching
- Regulatory Pathway
- Whether the topline pivotal data in Q2 2026 will support a successful pre-BLA meeting with the FDA and pave the way for regulatory approval.
- Clinical Efficacy
- The durability of functional improvements and cardiac stability observed in the Phase I/II trial as the confirmatory trial progresses.
- Competitive Positioning
- How RGX-202's differentiated microdystrophin construct and favorable safety profile will position it against existing and emerging therapies for Duchenne.
Related topics